NCT05288998Active, not recruiting
Intrarenal Microvasculature in ADPKD
Noninvasive Evaluation of the Intrarenal Microvasculature in ADPKD
Source: ClinicalTrials.gov · Last updated 16 Jan 2026
Brief summary (registry, in English)
The primary objective of this study is to evaluate the use of Super-resolution ultrasound (SRU) to assess the intrarenal microvasculature in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and healthy volunteers.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 34 (actual)
- First submitted
- 21 Feb 2022
- Start date
- 30 Nov 2021
- Primary completion date
- Dec 2026
- Lead sponsor
- Mayo Clinic
- Diseases
- Polycystic kidney disease
- NCT number
- NCT05288998
What you commit to
- Study type: Observational
- Participants enrolled: 34
- From 30 Nov 2021 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A concomitant systemic disease affecting the kidney (e.g., lupus, hepatitis B or C, amyloidosis)
- Concomitant systemic disease that may affect the kidney
Other illness
- History of hypersensitivity allergic reactions to ultrasound contrast agents
- High-risk cardiac disease (such as unstable hospital in-patients or ICU patients
- Family and/or personal history of kidney disease
- Diabetes mellitus
- History of hypersensitivity allergic reactions to ultrasound contrast agents
- High risk cardiac disease (such as unstable hospital in-patients or ICU patients
Lab values
- Diabetes mellitus (fasting glucose \> 126 mg/dL or treatment with insulin or oral hypoglycemics).
Other
- Class 2 according to imaging classification
- Predicted urine protein excretion in urinalysis \>1 g/24 hrs.
- Subjects having contraindications to or interference with MRI assessments. \[For example ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc.\].
- Patients that are part of an interventional study or are taking tolvaptan
- Female subjects that are pregnant
- Predicted urine protein excretion in \>1 g/24 hrs, and or Abnormal urinalysis
- Pregnant or lactating women
- Subjects having contraindications to or interference with MRI assessments. \[For example ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc.\].
Who the study is looking for
- Male and female subjects 18 - 40 years of age, inclusive
- Previous diagnosis of ADPKD (based on Ravine et al. criteria)
- Class 1 according to imaging classification
- Estimated GFR\> 90 mL/min/m2 (CKD-Epi equation)
- Ability to provide written, informed consent
- Male and female subjects 18 - 40 years of age, inclusive
- Estimated GFR\> 90 mL/min/m2 (CKD-Epi equation)
- Ability to provide written, informed consent
Age in the registry: 18 years to 40 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.